Treatment of the primary in metastatic prostate cancer

被引:5
作者
Gingu, Constantin [1 ,2 ]
Heidenreich, Axel [3 ]
Andresanu, Andrei [1 ]
Mihancea, Adrian [1 ]
Sinescu, Ioanel [1 ,2 ]
Baston, Catalin [1 ,2 ]
机构
[1] Fundeni Clin Inst, Ctr Uronephrol & Renal Transplantat, 258 Fundeni Ave,2nd Dist, Bucharest 022328, Romania
[2] Carol Davila Univ Med & Pharm Bucharest, Bucharest, Romania
[3] Univ Klinikum, Cologne, Germany
关键词
cytoreductive prostatectomy; metastases-directed therapy; oligometastatic; prostate cancer; radiotherapy; ANDROGEN-DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; DIRECTED THERAPY; LOCAL THERAPY; CYTOREDUCTIVE PROSTATECTOMY; BODY RADIOTHERAPY; PRIMARY TUMOR; CONTROL ARM; HIGH-RISK; SURVIVAL;
D O I
10.1097/MOU.0000000000000779
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review The standard treatment in metastatic prostate cancer (mPCa) is systemic, based on androgen deprivation therapy recommended in different forms, alone or combined with abiraterone acetate or docetaxel. The aim of this review is to synthesize the available data from literature regarding the optimal treatment of the primary in patients diagnosed with metastatic prostate cancer. Recent findings Multimodal treatments offer the best chance for survival for these patients, but the optimal strategy lacks consensus. Using retrospective studies as an argument, recent articles sustain the clinical and oncological benefits of local therapies in hormone-naive metastatic prostate cancer, represented by radical prostatectomy or radiotherapy. Through these procedures, local control of disease can be achieved, thus avoiding potential complications and further surgical interventions. Even if the current results are not evenly relevant, the treatment of the primary along with metastasis-directed therapy could improve survival and even cure-selected patients. Summary This article emphasizes important aspects regarding a feasible management of mPCa, with possible impact on subsequent guidelines. The expected results from ongoing trials may provide another perspective in treatment of these cases.
引用
收藏
页码:566 / 575
页数:10
相关论文
共 80 条
[31]   Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study [J].
Heidenreich, Axel ;
Pfister, David ;
Porres, Daniel .
JOURNAL OF UROLOGY, 2015, 193 (03) :832-838
[32]   OLIGOMETASTASES [J].
HELLMAN, S ;
WEICHSELBAUM, RR .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :8-10
[33]   A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol [J].
Hofman, Michael S. ;
Murphy, Declan G. ;
Williams, Scott G. ;
Nzenza, Tatenda ;
Herschtal, Alan ;
De Abreu Lourenco, Richard ;
Bailey, Dale L. ;
Budd, Ray ;
Hicks, Rodney J. ;
Francis, Roslyn J. ;
Lawrentschuk, Nathan .
BJU INTERNATIONAL, 2018, 122 (05) :783-793
[34]   Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls [J].
Hofman, Michael S. ;
Hicks, Rodney J. ;
Maurer, Tobias ;
Eiber, Matthias .
RADIOGRAPHICS, 2018, 38 (01) :200-217
[35]   Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer [J].
Hong, Matthew K. H. ;
Macintyre, Geoff ;
Wedge, David C. ;
Van Loo, Peter ;
Patel, Keval ;
Lunke, Sebastian ;
Alexandrov, Ludmil B. ;
Sloggett, Clare ;
Cmero, Marek ;
Marass, Francesco ;
Tsui, Dana ;
Mangiola, Stefano ;
Lonie, Andrew ;
Naeem, Haroon ;
Sapre, Nikhil ;
Phal, Pramit M. ;
Kurganovs, Natalie ;
Chin, Xiaowen ;
Kerger, Michael ;
Warren, Anne Y. ;
Neal, David ;
Gnanapragasam, Vincent ;
Rosenfeld, Nitzan ;
Pedersen, John S. ;
Ryan, Andrew ;
Haviv, Izhak ;
Costello, Anthony J. ;
Corcoran, Niall M. ;
Hovens, Christopher M. .
NATURE COMMUNICATIONS, 2015, 6
[36]   Tumour exosome integrins determine organotropic metastasis [J].
Hoshino, Ayuko ;
Costa-Silva, Bruno ;
Shen, Tang-Long ;
Rodrigues, Goncalo ;
Hashimoto, Ayako ;
Mark, Milica Tesic ;
Molina, Henrik ;
Kohsaka, Shinji ;
Di Giannatale, Angela ;
Ceder, Sophia ;
Singh, Swarnima ;
Williams, Caitlin ;
Soplop, Nadine ;
Uryu, Kunihiro ;
Pharmer, Lindsay ;
King, Tari ;
Bojmar, Linda ;
Davies, Alexander E. ;
Ararso, Yonathan ;
Zhang, Tuo ;
Zhang, Haiying ;
Hernandez, Jonathan ;
Weiss, Joshua M. ;
Dumont-Cole, Vanessa D. ;
Kramer, Kimberly ;
Wexler, Leonard H. ;
Narendran, Aru ;
Schwartz, Gary K. ;
Healey, John H. ;
Sandstrom, Per ;
Labori, Knut Jorgen ;
Kure, Elin H. ;
Grandgenett, Paul M. ;
Hollingsworth, Michael A. ;
de Sousa, Maria ;
Kaur, Sukhwinder ;
Jain, Maneesh ;
Mallya, Kavita ;
Batra, Surinder K. ;
Jarnagin, William R. ;
Brady, Mary S. ;
Fodstad, Oystein ;
Muller, Volkmar ;
Pantel, Klaus ;
Minn, Andy J. ;
Bissell, Mina J. ;
Garcia, Benjamin A. ;
Kang, Yibin ;
Rajasekhar, Vinagolu K. ;
Ghajar, Cyrus M. .
NATURE, 2015, 527 (7578) :329-+
[37]   Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy [J].
James, N. D. ;
de Bono, J. S. ;
Spears, M. R. ;
Clarke, N. W. ;
Mason, M. D. ;
Dearnaley, D. P. ;
Ritchie, A. W. S. ;
Amos, C. L. ;
Gilson, C. ;
Jones, R. J. ;
Matheson, D. ;
Miliman, R. ;
Attard, G. ;
Chowdhury, S. ;
Cross, W. R. ;
Gillessen, S. ;
Parker, C. C. ;
Russell, J. M. ;
Berthold, D. R. ;
Brawley, C. ;
Adab, F. ;
Aung, S. ;
Birtle, A. J. ;
Bowen, J. ;
Brock, S. ;
Chakraborti, P. ;
Ferguson, C. ;
Gale, J. ;
Gray, E. ;
Hingorani, M. ;
Hoskin, P. J. ;
Lester, J. F. ;
Malik, Z. I. ;
McKinna, F. ;
McPhail, N. ;
Money-Kyrle, J. ;
O'Sullivan, J. ;
Parikh, O. ;
Protheroe, A. ;
Robinson, A. ;
Srihari, N. N. ;
Thomas, C. ;
Wagstaff, J. ;
Wylie, J. ;
Zarkar, A. ;
Parmar, M. K. B. ;
Sydes, M. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :338-351
[38]   Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly-Diagnosed Non-Metastatic Prostate Cancer: Data From > 690 Patients in the Control Arm of the STAMPEDE Trial [J].
James, N. D. ;
Spears, M. R. ;
Clarke, N. W. ;
Sydes, M. R. ;
Parker, C. C. ;
Dearnaley, D. P. ;
Russell, J. M. ;
Ritchie, A. W. S. ;
Thalmann, G. ;
De Bono, J. S. ;
Attard, G. ;
Amos, C. ;
Parmar, M. K. ;
Mason, M. D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 :S13-S13
[39]   Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].
James, Nicholas D. ;
Sydes, Matthew R. ;
Clarke, Noel W. ;
Mason, Malcolm D. ;
Dearnaley, David P. ;
Spears, Melissa R. ;
Ritchie, Alastair W. S. ;
Parker, Christopher C. ;
Russell, J. Martin ;
Attard, Gerhardt ;
de Bono, Johann ;
Cross, William ;
Jones, Rob J. ;
Thalmann, George ;
Amos, Claire ;
Matheson, David ;
Millman, Robin ;
Alzouebi, Mymoona ;
Beesley, Sharon ;
Birtle, Alison J. ;
Brock, Susannah ;
Cathomas, Richard ;
Chakraborti, Prabir ;
Chowdhury, Simon ;
Cook, Audrey ;
Elliott, Tony ;
Gale, Joanna ;
Gibbs, Stephanie ;
Graham, John D. ;
Hetherington, John ;
Hughes, Robert ;
Laing, Robert ;
McKinna, Fiona ;
McLaren, Duncan B. ;
O'Sullivan, Joe M. ;
Parikh, Omi ;
Peedell, Clive ;
Protheroe, Andrew ;
Robinson, Angus J. ;
Srihari, Narayanan ;
Srinivasan, Rajaguru ;
Staffurth, John ;
Sundar, Santhanam ;
Tolan, Shaun ;
Tsang, David ;
Wagstaff, John ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10024) :1163-1177
[40]   Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) [J].
James, Nicholas David ;
Spears, Melissa R. ;
Clarke, Noel W. ;
Dearnaley, David P. ;
De Bono, Johann S. ;
Gale, Joanna ;
Hetherington, John ;
Hoskin, Peter J. ;
Jones, Robert J. ;
Laing, Robert ;
Lester, Jason F. ;
McLaren, Duncan ;
Parker, Christopher C. ;
Parmar, Mahesh K. B. ;
Ritchie, Alastair W. S. ;
Russell, J. Martin ;
Strebel, Raeto T. ;
Thalmann, George N. ;
Mason, Malcolm D. ;
Sydes, Matthew R. .
EUROPEAN UROLOGY, 2015, 67 (06) :1028-1038